NTT: World's Largest Capacity of 1.2 Tbit/s Per Wavelength Achieved by Newly Developed Digital Coherent Signal Processing Circuit and Optical Device
NTT Corporation (NTT, Head office: Chiyoda-ku Tokyo; President & CEO: Akira Shimada) has developed a digital coherent signal processing circuit and optical device that achieves the world's largest capacity of 1.2 Tbit/s per wavelength for optical transmission, which is 1.5 times faster than before. With this development, NTT tackles the challenge of achieving advanced optical transmission technology that can economically and significantly expand the capacity of existing systems while reducing the power consumption of communication devices.
The technology has also achieved the world’s highest optical signal modulation speed of 140 Giga baud and enables double the previous world record optical transmission distance of 800 Gbit/s. As a result, the capacity of optical transmission systems will increase by 12 times and the power consumption per bit will be reduced to 10% of the widely used commercial system. The improvements in the performance and power consumption of optical transmission systems should contribute to the All-Photonics Network foundational to the IOWN1 concept.
Our digital coherent signal processing circuit combines cutting-edge coded modulation with transmission performance approaching the theoretical limit and newly developed forward error correction that can correct bit errors in large amounts of data with low power consumption. This results in flexible coded modulation that maximizes the potential of high-speed optical devices. Furthermore, by utilizing a power-efficient algorithm to equalize signal distortion in the optical fiber transmission channel and the advanced CMOS processes, we have achieved a digital signal processing of 1.2 Tbit/s per wavelength with low power consumption.
The transceiver consists of a cutting-edge digital coherent signal processing circuit and a 140-Giga baud class optical device with the world's widest-class opto-electrical response bandwidth. In our approach, by increasing the modulation speed from 100 Giga baud to 140 Giga baud, higher resistance to waveform distortion and optical amplification noise caused by transmission could be achieved. As a result, the previous record transmission distance of 800 Gbit/s signals can be extended by more than twice that of the 100 Giga baud devices.
Toward the development of IOWN, NTT aims to create an innovative network with high capacity, low latency, flexibility, and low power consumption by continuing to expand and develop end-to-end photonics technology. We will promote the creation of economical, large-capacity, low-power-consumption networks by leveraging advanced optical transmission systems based on innovative technology. We also intend to collaborate with both international and domestic partners so that our developments can be valuable and beneficial for communities worldwide. You can access the full report about this development here.
1 IOWN: https://group.ntt/jp/newsrelease/2019/05/09/190509b.html (Japanese)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005467/en/
Contact information
Media Contact
NTT Corporation
Science and Core Technology Laboratory Group, Public Relations Section
nttrd-pr@ml.ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom